Nebivolol Viatris Sante (Nebivolol Hydrochloride)

Nebivolol selectively blocks β1‑adrenergic receptors in the heart, reducing heart rate and contractility. In addition, it stimulates endothelial nitric‑oxide production, causing vasodilation. The combined effect decreases peripheral resistance and lowers systemic blood pressure.

The appropriate dose of nebivolol is determined by the prescribing clinician based on the patient’s medical condition, response to therapy, and any concomitant medications. Dosage adjustments may be needed for renal or hepatic impairment.

Safety data for nebivolol in pregnancy and lactation are limited. The drug should only be used if the potential benefit justifies the potential risk to the fetus or infant, and the decision must be made by a qualified healthcare professional.

To request Nebivolol Viatris Sante, submit an enquiry on the product page at gnhindia.com with the required quantity. GNH India supplies hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Nebivolol is a highly selective β1‑blocker that also promotes nitric‑oxide‑mediated vasodilation, which can result in fewer metabolic side effects compared with non‑selective beta‑blockers. Its dual action may offer better tolerability for some patients, though clinical choice depends on individual patient profiles.

Nebivolol Viatris Sante should be stored at room temperature, below 25 °C, in the original packaging. Protect the product from moisture and direct sunlight to maintain its stability and potency.

Nebivolol Viatris Sante is taken orally, usually once daily with or without food, as directed by the prescriber. The tablet should be swallowed whole with a glass of water and not chewed or crushed.

Serious risks include severe bradycardia, marked hypotension, heart block, bronchospasm in patients with reactive airway disease, and rare allergic reactions. Patients should be monitored for these events, especially during treatment initiation or dose changes.

Nebivolol is contraindicated in patients with known hypersensitivity to nebivolol or any excipients, those with severe bradycardia, second‑ or third‑degree atrioventricular block without a pacemaker, and individuals with uncompensated heart failure or cardiogenic shock.